Distress in patients with renal cell carcinoma: a curious gap in knowledge

Bergerot, Cristiane Decat; Battle, Dena; Staehler, Michael; Pal, Sumanta K.

doi:10.1111/bju.14564

Cited by 18 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study reveals that while patients experience heightened anxiety related to COVID-19, they remain substantially concerned about cancer recurrence and progression. The proportion of patients with moderate to severe anxiety related to COVID-19 or their cancer diagnosis was notably higher than that reported in previous studies [9]. As such, we observed that many patients with RCC are unwilling to compromise planned surveillance for localized disease or planned systemic therapy for metastatic disease.…”

Section: Discussioncontrasting

confidence: 67%

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

Staehler

Battle²,

Pal

et al. 2021

European Urology Focus

Self Cite

View full text Add to dashboard Cite

Background: While providers are challenged with treatment decisions during the coronavirus disease 2019 (COVID-19) crisis, decision making ultimately falls in the hands of patients-at present, their perspective is poorly understood. Objective: To ascertain renal cell carcinoma (RCC) patients' perspectives on COVID-19 and understand the associated implications for treatment. Design, setting, and participants: An online survey of RCC patients was conducted from March 22 to March 25, 2020, disseminated through social media and patient networking platforms. The survey comprised 45 items, including baseline demographic, clinicopathologic, and treatment-related information. Patients were additionally queried regarding their anxiety level related to COVID-19 and associated implications for their cancer diagnosis. Intervention: An online survey study. Outcome measurements and statistical analysis: Descriptive statistics with graphical outputs were used to characterize survey results. Results and limitations: A total of 539 patients (male:female 39%:58%) from 14 countries responded. Of them, 71% felt that their risk of COVID-19 infection was higher than the general population, and 27% contacted their physician to establish this. Among patients with localized disease (40%), most (42%) had scheduled surveillance scans within 6 wk-65% were unwilling to delay scans. Among patients with metastatic disease, 76% were receiving active therapy. While most patients preferred not to defer therapy (51%), patients receiving immune therapy regimens were less amenable to deferring therapy than those receiving targeted treatment (20% vs 47%). Conclusions: Despite high levels of anxiety surrounding COVID-19, many patients with RCC were inclined to adhere to existing schedules of surveillance (localized disease) and systemic treatment (metastatic disease). Patient summary: The coronavirus disease 2019 (COVID-19) pandemic has prompted many doctors to develop different treatment strategies for cancer and other chronic conditions. Given the importance of the patient voice in these strategies, we conducted a survey of patients with kidney cancer to determine their treatment preferences. Our survey highlighted that most patients prefer to continue their current strategies of kidney cancer treatment and monitoring.

show abstract

Section: Discussioncontrasting

confidence: 67%

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

Staehler

Battle²,

Pal

et al. 2021

European Urology Focus

Self Cite

View full text Add to dashboard Cite

show abstract

“…In another recent survey on 450 patients with RCC (nonmetastatic RCC: 74%; disease recurrence: 61%; ccRR: 76%) [54], distress was significantly associated with female gender, younger age, non-ccRCC, and the presence of recurrence.…”

Section: Differences In Psychological Distressmentioning

confidence: 96%

Gender-Related Approach to Kidney Cancer Management: Moving Forward

Mancini

Righetto

Baggio

2020

IJMS

View full text Add to dashboard Cite

Men are more frequently diagnosed with kidney cancer than women, with a more aggressive histology, larger tumors, a higher grade and stage, and worse oncological outcomes. Smoking habits and sex steroid hormones seem to have a possible role in explaining these gender disparities. Moreover, the expression of genes involved in tumor growth and immune response in kidney cancer varies between men and women, having an impact on the gender-related response to oncological therapy, such as anti-angiogenic drugs and immunotherapy. Recent advances have been made in our understanding of the molecular and genetic mechanisms involved in kidney cancer, which could partially explain the gender differences, and they are summarized in this paper. However, other key mechanisms, which fully clarify the striking clinical gender-related differences observed in kidney cancer, are not completely understood at present. We reviewed and summarized the most relevant publications about the relationship between gender and kidney cancer. Efforts should be made to progress in bench and clinical research on gender-related signatures and disparities, and their impact on the clinical management of kidney cancer.

show abstract

“…Strong positive co-associations with increased tumor mutational burden and immune checkpoint inhibitor efficacy was observed as the consequence of exposure to several mutagenic causative factors—such as ultraviolet light for melanoma and tobacco smoke for non-small-cell lung cancer. Subjective feelings such as self-concept, happiness, optimism, the use of coping strategies, family functioning and social support are correlated in cancer patients with better psychosocial quality of life [ 139 ] and may differ across gender [ 140 ]. Although women suffer from stress-related psychiatric disorders more frequently, paradoxically they seem more capable of coping with a disease such as cancer and favorably influencing its outcome.…”

Section: The Role Of Gender In Cancer Immunotherapymentioning

confidence: 99%

Sex and Gender Influences on Cancer Immunotherapy Response

et al. 2020

View full text Add to dashboard Cite

The global burden of cancer is growing and a wide disparity in the incidence, malignancy and mortality of different types of cancer between each sex has been demonstrated. The sex specificity of cancer appears to be a relevant issue in the management of the disease, and studies investigating the role of sex and gender are becoming extremely urgent. Sex hormones are presumably the leading actors of sex differences in cancer, especially estrogens. They modulate gene expression, alter molecules and generate disparities in effectiveness and side effects of anticancer therapies. Recently immunotherapy aims to improve anticancer treatment strategies reducing off-target effects of chemotherapy and direct cancer cells killing. It is recognized as a fruitful strategy to treat and possible to cure cancer. Immunotherapeutic agents are used to activate or boost the activation of the immune system to fight cancer cells through physiological mechanisms often evaded in the offensive march of the disease. These therapeutic strategies have allowed new successes, but also have serious adverse effects including non-specific inflammation and autoimmunity. Sex and gender issues are of primary importance in this field, due to their recognized role in inflammation, immunity and cancer, and the clarification and understanding of these aspects is a necessary step to increase the responses and to diminish the adverse effects of immunotherapy. This review describes the available knowledge on the role of sex and gender in cancer immunotherapy, and will offer insights to stimulate the attention and practice of clinicians and researchers in a gender perspective of new cancer treatment strategies.

show abstract

Distress in patients with renal cell carcinoma: a curious gap in knowledge

Cited by 18 publications

References 9 publications

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

Counterbalancing COVID-19 with Cancer Surveillance and Therapy: A Survey of Patients with Renal Cell Carcinoma

Gender-Related Approach to Kidney Cancer Management: Moving Forward

Sex and Gender Influences on Cancer Immunotherapy Response

Contact Info

Product

Resources

About